DOCSLIB.ORG

Subunit Α Receptor Shedding of the Cell Surface GM-CSF Monocytes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subunit Α Receptor Shedding of the Cell Surface GM-CSF Monocytes Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human This information is current as Monocytes: Evidence for Ectodomain of September 25, 2021. Shedding of the Cell Surface GM-CSF Receptor α Subunit Jay M. Prevost, Jennifer L. Pelley, Weibin Zhu, Gianni E. D'Egidio, Paul P. Beaudry, Carin Pihl, Graham G. Neely, Downloaded from Emmanuel Claret, John Wijdenes and Christopher B. Brown J Immunol 2002; 169:5679-5688; ; doi: 10.4049/jimmunol.169.10.5679 http://www.jimmunol.org/content/169/10/5679 http://www.jimmunol.org/ References This article cites 39 articles, 19 of which you can access for free at: http://www.jimmunol.org/content/169/10/5679.full#ref-list-1 Why The JI? Submit online. by guest on September 25, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Inflammatory Stimuli Up-Regulate Secretion of the Soluble GM-CSF Receptor in Human Monocytes: Evidence for Ectodomain Shedding of the Cell Surface GM-CSF Receptor ␣ Subunit1 Jay M. Prevost,2* Jennifer L. Pelley,2*† Weibin Zhu,* Gianni E. D’Egidio,* Paul P. Beaudry,‡ Carin Pihl,* Graham G. Neely,§ Emmanuel Claret,¶ John Wijdenes,¶ and 3 ʈ Christopher B. Brown * Downloaded from Soluble GM-CSF receptor ␣ subunit (sGMR␣) is a soluble isoform of the GMR␣ that is believed to arise exclusively through alternative splicing of the GMR␣ gene product. The sGMR␣ mRNA is expressed in a variety of tissues, but it is not clear which cells are capable of secreting the protein. We show here that normal human monocytes, but not lymphocytes, constitutively secrete sGMR␣. Stimulation of monocytes with GM-CSF, LPS, PMA, or A23187 rapidly up-regulates the secretion of sGMR␣ in a http://www.jimmunol.org/ dose-dependent manner, demonstrating that secretion is also regulated. To determine whether sGMR␣ arose exclusively through alternative splicing of the GMR␣ gene product, or whether it could also be generated through ectodomain shedding of GMR␣, we engineered a murine pro-B cell line (Ba/F3) to express exclusively the cDNA for cell surface GMR␣ (Ba/F3.GMR␣). The Ba/F3.GMR␣ cell line, but not the parental Ba/F3 cell line, constitutively shed a sGMR␣-like protein that bound specifically to GM-CSF, was equivalent in size to recombinant alternatively spliced sGMR␣ (60 kDa), and was recognized specifically by a mAb raised against the ectodomain of GMR␣. Furthermore, a broad-spectrum metalloprotease inhibitor (BB94) reduced constitutive and PMA-, A23187-, and LPS-induced secretion of sGMR␣ by monocytes, suggesting that shedding of GMR␣ by monocytes may be mediated in part through the activity of metalloproteases. Taken together, these observations demonstrate that sGMR␣ is constitutively secreted by monocytes, that GM-CSF and inflammatory mediators up-regulate sGMR␣ secretion, and that sGMR␣ by guest on September 25, 2021 arises not only through alternative splicing but also through ectodomain shedding of cell surface GMR␣. The Journal of Im- munology, 2002, 169: 5679–5688. M-CSF is a multifunctional cytokine that mediates its GMR␣ is also expressed as an alternatively spliced soluble iso- hematopoietic and inflammatory activities (1) through a form, soluble GMR␣ (sGMR␣). sGMR␣ arises through alternative membrane-spanning cell surface receptor that consists of splicing of the parental GMR␣ gene product (4–7). Exclusion of G 4 a ligand-binding subunit, GM-CSF receptor ␣ subunit (GMR␣) the exon that encodes the transmembrane domain of GMR␣ results (2), and a signal-transducing subunit, ␤c (3). GMR␣ is a 378-aa in translation of a protein that is missing both the membrane-span- protein that consists of a 298-aa extracellular domain, a 26-aa ning domain of GMR␣ and the cytoplasmic domain, but that re- membrane-spanning domain, and a 54-aa cytoplasmic domain (2). tains the 295-aa GMR␣ ectodomain. In addition, the alternative splicing event generates a frameshift in the coding sequence that results in the addition of 16-aa to the carboxy terminus of the *Cancer Biology Research Group, Southern Alberta Cancer Research Center, De- sGMR␣ protein. partments of †Biochemistry and Molecular Biology, ‡Surgery, and §Medical Science, sGMR␣ has been cloned and expressed as a recombinant protein University of Calgary, Calgary, Alberta, Canada; ¶Diaclone Research, Besancon, ʈ ␣ France; and Alberta Bone Marrow and Stem Cell Transplant Program (5–7). Recombinant sGMR is a heavily glycosylated 60-kDa pro- Received for publication January 16, 2002. Accepted for publication September tein that binds GM-CSF in solution with the same affinity as cell ␣ ϭ 17, 2002. surface GMR (Kd 2–10 nM) (2, 7). However, unlike cell sur- The costs of publication of this article were defrayed in part by the payment of page face GMR␣, which binds GM-CSF then associates with ␤c, an charges. This article must therefore be hereby marked advertisement in accordance exogenous source of sGMR␣ added to ␤c-expressing cells will not with 18 U.S.C. Section 1734 solely to indicate this fact. associate with ␤c, whether in the presence or absence of GM-CSF 1 This work was supported by grants from the Canadian Institutes of Health Research and the Arthritis Society of Canada (to C.B.B.). J.L.P. is the recipient of a studentship (8, 9). Instead, sGMR␣ antagonizes the function of GM-CSF in award from the Canadian Institutes of Health Research. vitro by binding to it and preventing it from interacting with the 2 J.M.P. and J.L.P. contributed equally to this work. cell surface GMR␣/␤c complex (7). sGMR␣ has also been shown 3 Address correspondence and reprint requests to Dr. Christopher B. Brown, Depart- to inhibit the proliferation of GM-CSF-dependent cell lines (5, 6, ments of Medicine and Oncology, University of Calgary, Heritage Medical Research Building, Room 311, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1. 10) and to inhibit bone marrow colony formation (7). E-mail address: [email protected] The alternatively spliced GMR␣ message is expressed by a va- 4 Abbreviations used in this paper: GMR␣, GM-CSF receptor ␣ subunit; s, soluble. riety of cell types, including human placental tissue (7), myeloid Copyright © 2002 by The American Association of Immunologists, Inc. 0022-1767/02/$02.00 5680 ECTODOMAIN SHEDDING OF GMR␣ IN MONOCYTES leukemic cell lines (5, 6, 11), bone marrow progenitors, monocyte/ sity centrifugation over Ficoll. The enriched mononuclear cell layer typi- ϩ macrophages, and synovial fibroblasts (6). Less is known about the cally consisted of 75–85% CD14 monocytes. ␣ expression of the alternatively spliced sGMR protein. A soluble Flow cytometry GM-CSF binding protein was identified in medium conditioned by a human choriocarcinoma cell line (JEG-3) (12), but no immuno- The percentage of monocytes in either the PBMC preparations or the monocyte-enriched/depleted preparations was determined by CD14 stain- logical or biochemical data were presented as to whether this pro- ing and FACS. Briefly, 106 cells were stained for 15 min on ice with 0.5 tein was equivalent to alternatively spliced sGMR␣. However, a ␮g of a FITC-labeled mouse anti-human CD14 mAb or an IgG2a-FITC 60-kDa soluble GM-CSF binding protein was recently identified in isotype control mAb (BD PharMingen, San Diego, CA). The cells were medium conditioned by human myeloid leukemic cell lines (U937, washed and fixed in PBS containing 1% PBS-buffered formalin. Data were THP-1, and HL-60), by normal human granulocytes, and in normal acquired using a FACStation flow cytometer (BD Biosciences) and were analyzed using Flowjo (Treestar, San Carlos, CA). The expression of human plasma (13). This protein migrated as a 60-kDa band by GMR␣ on the cell surface was determined in a similar manner using 1 ␮g SDS-PAGE, was recognized by a mAb that was raised against the of a mouse anti-human GMR␣ mAb (8G6; a gift of Dr. A. Lopez, Hansen ectodomain of GMR␣, and bound GM-CSF with the same affinity Center for Cancer Research, Adelaide, Australia) or an equivalent murine ␮ as recombinant alternatively spliced sGMR␣, suggesting that these IgG1 isotype control (Sigma-Aldrich), followed by staining with 0.5 gof a PE-labeled F(abЈ) goat anti-mouse Ab (Calbiochem). two proteins were equivalent. 2 We were interested in determining whether normal human Detection of total sGMR␣ protein by ELISA ␣ monocytes, which express both cell surface GMR and the mRNA Supernatants from cell culture experiments were screened by ELISA for for sGMR␣, could also secrete the alternatively spliced sGMR␣ the presence of all sGMR␣ protein (sCD116 ELISA; Diaclone Research, protein. We were also interested in determining whether the se- Besancon, France). The sCD116 ELISA uses a capture mAb raised against Downloaded from cretion of alternatively spliced sGMR␣ by monocytes could be the ectodomain of GMR␣ (SCO6), whereas the detection mAb (SCO4) was also raised against the ectdomain of GMR␣. Because of this, the sCD116 regulated by GM-CSF and other stimuli. Using an ELISA that ␣ ␣ ELISA is not specific for alternatively spliced sGMR but instead recog- recognized all soluble isoforms of GMR , we found that mono- nizes any sGMR␣ isoform that shares the common ectodomain of GMR␣.
Load more

Recommended publications
  • Study Protocol: Amendment 3
    (!') GILEAU CLINICAL STUDY PROTOCOL Study Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel combined with Momelotinib in Subjects with Previously Unu·eated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-fmding, Lead-in Phase Sponsor: Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA IND Number: 120605 EudraCT Number: 2014-004480-20 ClinicalTrials.gov Identifier: NCT021 01021 Indication: Previously unu·eated metastatic pancreatic ductal adenocarcinoma Protocol ID: GS-US-370-1296 Clinical Trials Manager: Name: PPD Telephone: PPD Gilead Medical Monitor: Name: Peter Lee, MD, PhD Telephone: PPD Clinical Program Manager: Name: PPD Telephone: PPD Protocol Version/Date: Original: 11 Febmary 2014 Amendment 1: 14 March 2014 Amendment 2: 25 August 2014 Amendment 3: 16 July 2015 CONFIDENTIALITY STATEMENT The inf01mation contained in this document, pruiicularly unpublished data, is the prope1iy or under conu·ol of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The infonnation is only to be used by you in connection with authorized clinical studies of the investigational dmg described in the protocol. You will not disclose any of the infonnation to others without written authorization from Gilead Sciences, Inc., except to the extent necessa1y to obtain infonned consent from those persons
    [Show full text]
  • Abstract Supplement
    2018 ABSTRACT SUPPLEMENT SAN FRANCISCO June 20-23 • Marriott Marquis Federation of Clinical Immunology Societies June 20-23, 2018 San Francisco, California FOCIS 2018 Abstract Supplement TABLE OF CONTENTS Abstracts by Subject Area …………………………………………………………...……………………………….2 Allergy/asthma ……………………………………………………………………………………………………...2 Autoimmune neurologic diseases .............................................................................................................. 7 Autoimmune rheumatologic diseases ...................................................................................................... 19 Bone marrow or stem cell transplantation ............................................................................................... 37 Cytokines/chemokines ............................................................................................................................ 42 Diabetes and other autoimmune endocrine diseases .............................................................................. 47 General Autoimmunity…………………………………………………………………………………………….58 Genetics .................................................................................................................................................. 70 Immune monitoring .................................................................................................................................. 74 Immunity & infection ................................................................................................................................ 82 Immunodeficiency:
    [Show full text]
  • Granulocyte Colony-Stimulating Factor (G-CSF)
    British Journal of Cancer (1999) 80(1/2), 229–235 © 1999 Cancer Research Campaign Article no. bjoc.1998.0344 Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response E Reyes1, I García-Castro2, F Esquivel1, J Hornedo2, H Cortes-Funes2, J Solovera3 and M Alvarez-Mon1 1Medicine/Immune System Diseases Oncology Service, Department of Medicine ‘Principe de Asturias’ University Hospital, Alcalá University, Carretera Madrid- Barcelona, Km 33.600, 28871 Alcalá de Henares, Madrid, Spain; 2Medical Oncology Department, ‘12 de Octubre’ University Hospital, Madrid, Spain; 3Amgen, S.A. Barcelona, Spain Summary Granulocyte colony-stimulation factor (G-CSF) is a cytokine that selectively promotes growth and maturation of neutrophils and may modulate the cytokine response to inflammatory stimuli. The purpose of this study was to examine the effect of G-CSF on ex vivo peripheral blood mononuclear cell (PBMC) functions. Ten patients with breast cancer were included in a clinical trial in which r-metHuG-CSF was administrered daily for 5 days to mobilize peripheral blood stem cells. Ten healthy women were also included as controls. Our data show that G-CSF treatment induces an increase in peripheral blood leucocyte, neutrophil, lymphocyte and monocyte counts. We have found a modulation in the percentages of CD19+, CD45+CD14+, CD4+CD45RA+ and CD4+CD45RO+ cells in PBMC fractions during G-CSF treatment. We have also found a significant reduction in the proliferative response of PBMC to mitogenic stimulation that reverted 14 days after the fifth and the last dose of G-CSF. Furthermore, it was not associated with significant changes in the pattern of cytokine production.
    [Show full text]
  • Cytokines As Cellular Pathophysiology of Many Diseases
    Review Mediators of Inflammation, 5, 417-423 (1996) CYTOKINES and their receptors are involved in the Cytokines as cellular pathophysiology of many diseases. Here we pre- sent a detailed review on cytokines, receptors and communicators signalling routes, and show that one important lesson from cytokine biology is the complex and diverse regulation of cytokine activity. The activ- cA ity of cytokines is controlled at the level of trans- R. Debets and H. F. J. Savelkoul cription, translation, storage, processing, post- translational modification, trapping, binding by soluble proteins, and receptor number and/or Department of Immunology, Erasmus University, function. Translation of this diverse regulation in P.O. Box 1738, 3000 DR Rotterdam, The Netherlands strategies aimed at the control of cytokine activity will result in the development of more specific and selective drugs to treat diseases. CACorresponding Author Key words: Control of activity, Cytokine, Interference in cytokine activity, Receptor, Signalling routes Introduction lation and act locally to restore homeostasis. Cytokines bind with high affinity to specific For over two decades, it has been recognized receptors on the surface of target cells. When that immune-competent cells produce peptide cytokine receptors are expressed on the cyto- mediators, now termed cytokines. Cytokines act kine-producing cell, autocrine cellular activation as chemical communicators between cells, but may be the result. If the receptor is expressed mostly not as effector molecules in their own on a neighbouring cell, binding may result in right. The biological function of many cytokines paracrine cytokine activation. These features is mediated through their ability to regulate could explain the sometimes high local concen- gene expression in target cells.
    [Show full text]
  • Following High-Dose Chemotherapy and Autologous Bone Marrow Transplantation
    Bone Marrow Transplantation, (1997) 19, 315–322 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 A phase I trial of recombinant human interleukin-1b (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation M Elkordy, M Crump, JJ Vredenburgh, WP Petros, A Hussein, P Rubin, M Ross, C Gilbert, C Modlin, B Meisenberg, D Coniglio, J Rabinowitz, M Laughlin, J Kurtzberg and WP Peters Duke University, Bone Marrow Transplant Program, Durham, NC, USA Summary: The use of lineage-specific hematopoietic growth factors such as GM-CSF and G-CSF shortens the duration of neu- We studied the effects of escalating doses of recombi- tropenia following high-dose chemotherapy and ABMT.1–3 nant human IL-1b in patients receiving high-dose Recently with molecular cloning much interest has emerged chemotherapy and ABMT for metastatic breast cancer in the use of growth factors, which have multilineage pro- or malignant melanoma. Sixteen patients received IL- liferative effects, to shorten the duration of neutropenia and 1b, 4 to 32 ng/kg/day administered subcutaneously for platelet transfusion-dependence and to decrease the number 7 days beginning 3 h after bone marrow infusion. Three of red blood cell transfusions.4 patients at the highest dose level also received G-CSF IL-1b is a polypeptide which exerts effects on hemato- following completion of IL-1b. All patients completed poiesis through several mechanisms, and produces a broad the 7 days of therapy. The majority of patients experi- spectrum of metabolic, immunologic and inflammatory enced chills and fever following one or more injections, effects.5,6 In addition to having a direct stimulatory effect and seven had severe pain at the injection site.
    [Show full text]
  • The Immunomodulatory Impact of Multipotential Stromal Cells on Monocytes in Healthy People and Patients with Rheumatoid Arthritis
    The immunomodulatory impact of multipotential stromal cells on monocytes in healthy people and patients with rheumatoid arthritis Priyanka Dutta Submitted in accordance with the requirements for the degree of Doctor of Philosophy The University of Leeds Faculty of Medicine and Health School of Medicine September 2020 Primary Supervisor: Professor Michael McDermott Secondary Supervisor: Dr Elena Jones Secondary Supervisor: Professor Graham Cook The candidate confirms that the work submitted is her own work and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and no quotation from the thesis may be published without proper acknowledgement. The right of Priyanka Dutta to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. i Acknowledgements I would like to express my deep gratitude to my supervisors Professor Michael McDermott, Dr Elena Jones and Professor Graham Cook for providing me with this opportunity. Thank you for all your understanding, guidance and immense support inside and outside of the lab. Thanks for sharing your knowledge and ideas to support this PhD work, most of all thank you for your patience. Also, thanks to Chi Wong, Rekha Parmar, Adam Davidson and Elizabeth Straszynski for their great support in the lab, as well as the staff and patients at Chapel Allerton Hospital for providing patient samples. Thank you to Professor Paul Genever for providing the Y201 and Y202 MSC immortalised cell lines and to Dr Andreia Riberio and Professor Rhodri for their expert advice on optimisation of the whole blood assay.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0237439 A1 Stolen Et Al
    US 2013 02374.39A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0237439 A1 Stolen et al. (43) Pub. Date: Sep. 12, 2013 (54) SYSTEMIS AND METHODS USING Publication Classification BOMARKERPANEL, DATA (71) Applicants: Craig M. Stolen, New Brighton, MN (51) Int. Cl. (US); Timothy E. Meyer, North Oaks, GOIN33/68 (2006.01) MN (US); Milan Seth, Minneapolis, MN (52) U.S. Cl. (US); Francis G. Spinale, Blythewood, CPC .................................. G0IN33/6893 (2013.01) SC (US); Nicholas David Wold, Arden USPC .............................................. 506/9; 435/7.92 Hills, MN (US) (72) Inventors: Craig M. Stolen, New Brighton, MN (US); Timothy E. Meyer, North Oaks, (57) ABSTRACT MN (US); Milan Seth, Minneapolis, MN (US); Francis G. Spinale, Blythewood, SC (US); Nicholas David Wold, Arden Embodiments of the disclosure are related to systems and Hills, MN (US) methods for utilizing biomarker panel data with respect to (73) Assignees: MEDICAL UNIVERSITY OF medical devices and methods, amongst other things. In an SOUTH CAROLINA, CHARLESTON, embodiment, the disclosure can include a method of predict SC (US); CARDIAC PACEMAKERS, ing the likelihood of response to CRT therapy. The method INC., ST. PAUL, MN (US) can include quantifying levels of one or more biomarkers in a (21) Appl. No.: 13/756,129 biological sample of a patient, analyzing the quantified levels to determine response to CRT therapy, wherein a panel of (22) Filed: Jan. 31, 2013 biomarkers includes at least two selected from the group Related U.S. Application Data consisting of CRP, SGP-130, SIL-2R, STNFR-II, IFNg, BNP (60) Provisional application No.
    [Show full text]
  • Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications
    Review Cytokine Signaling in Multiple Sclerosis and Its Therapeutic Applications Pushpalatha Palle 1,2,†, Kelly L. Monaghan 1,2,†, Sarah M. Milne 1,2 and Edwin C.K. Wan 1,2,* 1 Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, WV 26506, USA; [email protected] (P.P.); [email protected] (K.L.M.); [email protected] (S.M.M.) 2 Center for Basic and Translational Stroke Research and the Center for Neurodegenerative Diseases, Blanchette Rockefeller Neurosciences Institute, West Virginia University School of Medicine, Morgantown, WV 26506, USA * Correspondence: [email protected]; Tel.: +1‐304‐263‐6293; Fax: +1‐304‐293‐7823 † These authors contributed equally to this work. Received: 22 August 2017; Accepted: 11 October 2017; Published: 13 October 2017 Abstract: Multiple sclerosis (MS) is one of the most common neurological disorders in young adults. The etiology of MS is not known but it is widely accepted that it is autoimmune in nature. Disease onset is believed to be initiated by the activation of CD4+ T cells that target autoantigens of the central nervous system (CNS) and their infiltration into the CNS, followed by the expansion of local and infiltrated peripheral effector myeloid cells that create an inflammatory milieu within the CNS, which ultimately lead to tissue damage and demyelination. Clinical studies have shown that progression of MS correlates with the abnormal expression of certain cytokines. The use of experimental autoimmune encephalomyelitis (EAE) model further delineates the role of these cytokines in neuroinflammation and the therapeutic potential of manipulating their biological activity in vivo.
    [Show full text]
  • An Emerging Role for the Anti-Inflammatory Cytokine
    Tsai et al. Journal of Biomedical Science 2013, 20:40 http://www.jbiomedsci.com/content/20/1/40 REVIEW Open Access An emerging role for the anti-inflammatory cytokine interleukin-10 in dengue virus infection Tsung-Ting Tsai1,2, Yi-Jui Chuang2,3, Yee-Shin Lin1,3,4, Shu-Wen Wan3,4, Chia-Ling Chen3,4 and Chiou-Feng Lin1,2,3,4* Abstract Infection with dengue virus (DENV) causes both mild dengue fever and severe dengue diseases, such as dengue hemorrhagic fever and dengue shock syndrome. The pathogenic mechanisms for DENV are complicated, involving viral cytotoxicity, immunopathogenesis, autoimmunity, and underlying host diseases. Viral load correlates with disease severity, while the antibody-dependent enhancement of infection largely determines the secondary effects of DENV infection. Epidemiological and experimental studies have revealed an association between the plasma levels of interleukin (IL)-10, which is the master anti-inflammatory cytokine, and disease severity in patients with DENV infection. Based on current knowledge of IL-10-mediated immune regulation during infection, researchers speculate an emerging role for IL-10 in clinical disease prognosis and dengue pathogenesis. However, the regulation of dengue pathogenesis has not been fully elucidated. This review article discusses the regulation and implications of IL-10 in DENV infection. For future strategies against DENV infection, manipulating IL-10 may be an effective antiviral treatment in addition to the development of a safe dengue vaccine. Keywords: DENV, Antibody-dependent
    [Show full text]
  • Hematologie 2021 POST-ASH
    ONLINE 21. PRAŽSKÉ HEMATOLOGICKÉ DNY Hematologie 2021 POST-ASH KAM NÁS POSOUVÁ TO NEJLEPŠÍ Z LOŇSKÉ SVĚTOVÉ HEMATOLOGIE 28. – 29. 1. 2021 Clarion Congress Hotel Prague (Freyova 33, Praha 9 – Vysočany) PROGRAM KONFERENCE A SBORNÍK ABSTRAKTŮ 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 OBSAH 2 POST-ASH OBSAH 2 ÚVODNÍ SLOVO 3 DŮLEŽITÉ INFORMACE 4 SCHÉMA ODBORNÉHO PROGRAMU 6 PODROBNÝ PROGRAM KONFERENCE 7 POSTEROVÁ SEKCE 11 OŠETŘOVATELSKÝ PROGRAM 16 SATELITNÍ SYMPOZIA 18 SBORNÍK ABSTRAKTŮ 25 ABECEDNÍ REJSTŘÍK AUTORŮ 119 PŘEHLED PARTNERŮ A VYSTAVOVATELŮ 122 21. PRAŽSKÉ HEMATOLOGICKÉ DNY ONLINE Hematologie 2021 28. – 29. 1. 2021 ÚVODNÍ SLOVO 3 POST-ASH Vážené kolegyně, vážení kolegové, milí hosté 21 pražských hematologických dnů-HEMATOLOGIE 2021, loni jsme na 20 pražských hematologických dnech zahájili novou tradici, kterou účastníci velmi přivítali: uspořádat konferenci na začátku roku a reflektovat při nich to nejlepší, co se v našem oboru odehrálo na loňských světových kongresech Jsou to především ASH a EHA, ale i více specializované konference I když celý loňský rok poznamenala pandemie, bylo nám celou dobu jasné, že úspěšnou tradici nesmíme přerušit Optimisté v našich řadách doufali, že se podaří uspořádat konferenci v klasickém formátu, nicméně připravovali jsme paralelně všechny varianty Nakonec zvítězila varianta výhradně online Podobně jako našim dětem chybí interakce se spolužáky, i my budeme postrádat milá setkání s kolegy, hovory ve frontě na kávu, diskusi v přednáškových sálech i chutný štrůdl v hotelu
    [Show full text]
  • Effects of Biological Therapies on Molecular Features of Rheumatoid
    International Journal of Molecular Sciences Review Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis , Chary Lopez-Pedrera * y , Nuria Barbarroja y, Alejandra M. Patiño-Trives, Maria Luque-Tévar, Eduardo Collantes-Estevez , Alejandro Escudero-Contreras z and Carlos Pérez-Sánchez z Rheumatology Service, Reina Sofia Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, E-14004 Córdoba, Spain; [email protected] (N.B.); [email protected] (A.M.P.-T.); [email protected] (M.L.-T.); [email protected] (E.C.-E.); [email protected] (A.E.-C.); [email protected] (C.P.-S.) * Correspondence: [email protected] or [email protected]; Tel.: +34-957-213-795 These authors shared first authorship. y These authors shared last authorship. z Received: 31 October 2020; Accepted: 27 November 2020; Published: 28 November 2020 Abstract: Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease primarily affecting the joints, and closely related to specific autoantibodies that mostly target modified self-epitopes. Relevant findings in the field of RA pathogenesis have been described. In particular, new insights come from studies on synovial fibroblasts and cells belonging to the innate and adaptive immune system, which documented the aberrant production of inflammatory mediators, oxidative stress and NETosis, along with relevant alterations of the genome and on the regulatory epigenetic mechanisms. In recent years, the advances in the understanding of RA pathogenesis by identifying key cells and cytokines allowed the development of new targeted disease-modifying antirheumatic drugs (DMARDs). These drugs considerably improved treatment outcomes for the majority of patients.
    [Show full text]
  • WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 1/36 (2006.01) A61K 38/19 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/28 (2006.01) A61M 1/34 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, PCT/IB2013/001583 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 3 1 May 2013 (3 1.05.2013) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, PCT/EP20 12/002340 1 June 2012 (01 .06.2012) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 12196527.
    [Show full text]